Michael Barbella, Managing Editor09.28.23
ZOLL has entered into an agreement with BrainCool to exclusively distribute the BrainCool System/IQool System and the IQool System Pads in the United States and key European markets. The pair also could potentially expand IQool distribution to select Asian markets.
The agreement broaden ZOLL’s temperature management solutions portfolio to include both intravascular technology and surface options, thus providing clinicians with choices for advanced solutions with precise temperature control and intelligent analytics.
“Expanding ZOLL’s temperature management offering to include a high-quality surface option supports our mission to improve patient outcomes and help save lives,” ZOLL Circulation President Christopher Barnabas stated. “With our Thermogard XP and Thermogard HQ products—the world’s only intravascular temperature management technology—and BrainCool’s IQool System, we now offer a combination of solutions that deliver high-quality patient care while recognizing hospitals’ evolving protocols and increased nursing workload.”
The BrainCool System (branded the IQool System in the United States) is an advanced surface temperature management system with gel-free and adhesive-free pads that maintains fever control and manages patient temperature in critical care settings. The IQool System features an intuitive user interface, programmable protocol settings and acute temperature control.
BrainCool AB is based in Lund, Sweden, and is listed on Nasdaq First North Growth Market.
ZOLL, an Asahi Kasei company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and cardiac monitoring, circulation enhancement and CPR feedback, supersaturated oxygen therapy, data management, ventilation, therapeutic temperature management, and sleep apnea diagnosis and treatment, ZOLL provides technologies that help clinicians, EMS and fire professionals, as well as lay rescuers, improve patient outcomes in critical cardiopulmonary conditions.
The Asahi Kasei Group has consistently grown since 1922 to meet the evolving needs of every age. With more than 46,000 employees worldwide, the company provides solutions to the world’s challenges through its three business sectors: Material, Homes, and Health Care. Its Health Care operations include devices and systems for acute critical care, dialysis, therapeutic apheresis, transfusion, and manufacture of biotherapeutics, as well as pharmaceuticals and diagnostic reagents.
The agreement broaden ZOLL’s temperature management solutions portfolio to include both intravascular technology and surface options, thus providing clinicians with choices for advanced solutions with precise temperature control and intelligent analytics.
“Expanding ZOLL’s temperature management offering to include a high-quality surface option supports our mission to improve patient outcomes and help save lives,” ZOLL Circulation President Christopher Barnabas stated. “With our Thermogard XP and Thermogard HQ products—the world’s only intravascular temperature management technology—and BrainCool’s IQool System, we now offer a combination of solutions that deliver high-quality patient care while recognizing hospitals’ evolving protocols and increased nursing workload.”
The BrainCool System (branded the IQool System in the United States) is an advanced surface temperature management system with gel-free and adhesive-free pads that maintains fever control and manages patient temperature in critical care settings. The IQool System features an intuitive user interface, programmable protocol settings and acute temperature control.
BrainCool AB is based in Lund, Sweden, and is listed on Nasdaq First North Growth Market.
ZOLL, an Asahi Kasei company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and cardiac monitoring, circulation enhancement and CPR feedback, supersaturated oxygen therapy, data management, ventilation, therapeutic temperature management, and sleep apnea diagnosis and treatment, ZOLL provides technologies that help clinicians, EMS and fire professionals, as well as lay rescuers, improve patient outcomes in critical cardiopulmonary conditions.
The Asahi Kasei Group has consistently grown since 1922 to meet the evolving needs of every age. With more than 46,000 employees worldwide, the company provides solutions to the world’s challenges through its three business sectors: Material, Homes, and Health Care. Its Health Care operations include devices and systems for acute critical care, dialysis, therapeutic apheresis, transfusion, and manufacture of biotherapeutics, as well as pharmaceuticals and diagnostic reagents.
